Making Personalized Cancer Care a Reality

My Immunotherapy Neo-Epitopes


Advaxis’ Lm Technology™ has proven to be an extremely versatile platform and is being investigated for use in treating a broad range of cancers by targeting tumor-specific mutations known as neoepitopes.  This approach has led to Advaxis’ MINE™ (My Immunotherapy Neo-Epitopes) program, with ADXS-NEO as the program’s lead product candidate.

“Personalized Medicine” has long been a popular catch-phrase for pharmaceutical companies, but to date no company has delivered on the promise of a truly personalized therapy.  ADXS-NEO creates a customized treatment with neoantigens specifically selected based on a biopsy of the patient’s tumor.  Working in partnership with Amgen, we are proud to be developing a truly personalized solution for oncology patients. 

This development strategy eliminates the need for predictive algorithms, enabling the development of truly tailored immunotherapies.



The first immunotherapy candidate leveraging the MINE™ technology, ADXS-NEO, is a customized cancer treatment with promising implications across several cancers. Through a parallel manufacturing system, the production of ADXS-NEO is designed to be easily scalable, cost-effective, and timely for patients. Further details on the potential of ADXS-NEO can be found in new white paper.

Developing the ADXS-NEO immunotherapy begins with a biopsy of the primary tumor and/or metastases, along with the patient’s normal cells, to identify non-synonymous mutations, or neoepitopes. These are then sent for exome sequencing, where a mutational map of the tumor is developed that can be used to select a set of neoepitopes most likely to be immunogenic.

Advaxis uses its Lm Technology™ to integrate coding sequences for these tumor-associated neoepitopes into a plasmid-based system that expresses them in the context of a fusion protein sequence including a fragment of the LLO molecule. The Lm vector is taken up by the antigen-presenting cells. Within the vector, large quantities of proteins with the mutated neoepitope are generated and secreted into the cytosol of the antigen-presenting cells, wherein they are processed and used to activate tumor-specific T cells, which can then find the cancer cells and destroy them. ADXS-NEO constructs also are designed to neutralize tumor protecting mechanisms by reducing the immune-suppressive activities of Tregs and myeloid-derived suppressor cells in the tumor microenvironment. Because the immune response is activated only against the mutated neoepitopes, little-to-no systemic blockade of tolerance and no off-target toxicity is expected.

The MINE program is expected to enter the clinic in 2017 using ADXS-NEO vectors to target patients’ unique, tumor-specific neoepitopes, in collaboration with Amgen.


Advaxis’ other neoantigen program using MINE technology , ADXS-HOT, leverages public so-called “hotspot” neoantigen mutations to create off-the-shelf targeted cancer immunotherapies.  These therapies will address the most commonly appearing mutations in many different types of cancer.  DNA sequencing is not required for ADXS-HOT, and the presence of the “hotspot” target can usually be determined by a rapid biomarker test, allowing treatment to begin quickly.


HPV-Associated Cancers

PSA-Associated Cancers


Mailing List

Sign up for email alerts for Press Releases and Advaxis breaking news.

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.